Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A blood coagulation factor Xa inhibitor containing bicyclic amide structure and its application

A technology of venous thrombosis and compound, applied in FXa inhibitor containing bicyclic amide structure, pharmaceutical field

Active Publication Date: 2016-06-01
浙江西塘实业有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

DVT also puts patients at high risk of developing pulmonary thromboembolism

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A blood coagulation factor Xa inhibitor containing bicyclic amide structure and its application
  • A blood coagulation factor Xa inhibitor containing bicyclic amide structure and its application
  • A blood coagulation factor Xa inhibitor containing bicyclic amide structure and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] The synthesis of embodiment 1 compound I

[0018]

[0019] A. Synthesis of Compound III

[0020] Compound II (1.26g, 10mmol) and triethylamine (3.04g, 30mmol) were dissolved in 10mL of dry DMF, stirred under cooling in an ice-water bath, slowly added dropwise from triphenylchloromethane (TrCl; 3.07g, 11mmol) and 10 mL of dry DMF solution. After the addition was complete, the resulting reaction mixture was stirred at room temperature for 3 hours, and TLC showed that the reaction was complete. The reaction mixture was poured into 120 mL of ice water, CH 2 Cl 2 (50mL×3) was extracted, and the extract phases were combined, washed with brine, and dried over anhydrous sodium sulfate. The desiccant was removed by suction filtration, the filtrate was evaporated to dryness on a rotary evaporator, and the obtained residue was purified by column chromatography to obtain compound III, a white solid, ESI-MS, m / z=369 ([M+H] + ).

[0021] B. Synthesis of Compound V-1

[002...

Embodiment 2

[0027] The synthesis of embodiment 2 reference compound D-1

[0028] Compound D-1 is also a compound designed by the present inventors in the course of research (not yet disclosed).

[0029]

[0030] A. Synthesis of Compound III

[0031] Compound II (1.26g, 10mmol) and triethylamine (3.04g, 30mmol) were dissolved in 10mL of dry DMF, stirred in an ice-water bath, slowly added dropwise from triphenylchloromethane (TrCl; 3.07g, 11mmol) and 10 mL of dry DMF solution. After the addition was complete, the resulting reaction mixture was stirred at room temperature for 3 hours, and TLC showed that the reaction was complete. The reaction mixture was poured into 120 mL of ice water, CH 2 Cl 2 (50mL×3) was extracted, and the extract phases were combined, washed with brine, and dried over anhydrous sodium sulfate. The desiccant was removed by suction filtration, the filtrate was evaporated to dryness on a rotary evaporator, and the obtained residue was purified by column chromat...

Embodiment 3

[0038] Inhibitory test of embodiment 3 compound to FXa in vitro

[0039] 5% DMSO solution (10 μ L) of the embodiment compound to be tested and positive drug EDOXABAN (its concentration is set appropriately step by step), Tris buffer solution (100 mM Tris, 200 mM potassium chloride, 0.2% BSA, pH7.4) (40 μ l) and 0.0625U / mL human FXa (EnzymeResearchLabolatories, Inc., dissolved and diluted (10 μl) with Tris buffer solution were put into the wells of a 96-well microplate, and a 750 μM aqueous solution (40 μl) of S2222 (Chromogenix Co.) was added to measure 10 Absorbance at 405 nm at room temperature for 1 minute, thereby measuring absorbance increase (ΔOD / min).As a negative control, Tris buffer was used instead of test compound.

[0040] According to the following formula, the percent inhibitory rate (%) at the initial concentration of the test compound and the final concentration of the test compound are respectively plotted on the ordinate and abscissa of the logarithmic orth...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines related to venous thromboembolic diseases, and particularly relates to an FXa inhibitor containing a bicycle-amide structure, a preparation method of the FXa inhibitor and application of the FXa inhibitor in preparation of medicines for treating venous thromboembolic diseases. The inhibitor structure is as shown in the specification.

Description

technical field [0001] The invention relates to the field of drugs for the treatment of venous thrombosis diseases. More specifically, the present invention relates to a FXa inhibitor containing a bicyclic amide structure that has a therapeutic effect on venous thrombosis, its preparation method, and its use in pharmacy. Background technique [0002] Deterioration of coagulation ability is unstable angina, cerebral infarction, cerebral embolism, myocardial infarction, pulmonary infarction, pulmonary embolism, thromboangiitis obliterans, deep vein thrombosis, disseminated intravascular coagulation syndrome, after valve replacement An important factor in thrombosis during revascularization, reocclusion after revascularization, or thrombosis during cardiopulmonary bypass. In the arterial system, abnormal thrombosis is mainly related to coronary arteries, cerebrovascular and peripheral blood vessels, and diseases related to thrombotic closure of these vessels mainly include acu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D471/04A61P7/02
CPCC07D471/04
Inventor 蔡子洋
Owner 浙江西塘实业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com